Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Chief Medical Officer | July 01, 2026 | July 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date July 01, 2026 · Filed July 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-01 · Exercise / conversion · Acquired 8,334 · Balance 8,334 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Row 2 · 2026-07-01 · Sale · Disposed 6,500 · Balance 1,834 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-07-01 · Sale · Disposed 1,834 · Balance 0 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.46 · Expires 2034-10-01 | Direct | 305,000 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Exercise / conversion · Disposed 8,334 · Balance 305,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,334 | $0.00 Strike: $27.46 | $0.00 |
DisclosureSEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · derivative · entry 4 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 8,334 shares Expires 2034-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,834 | $88.34 | $162,015.56 |
DisclosureSEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · nonDerivative · entry 3 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 6,500 | $87.52 | $568,880.00 |
DisclosureSEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · nonDerivative · entry 2 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,834 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 8,334 | $27.46 | $228,851.64 |
DisclosureSEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · nonDerivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,333 | $0.00 Strike: $27.46 | $0.00 |
DisclosureSEC source: 0001636282-26-000078 · wk-form4_1780536719.xml · derivative · entry 3 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,334 Underlying: Common Stock · 8,333 shares Expires 2034-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 8,333 | $75.00 | $624,975.00 |
DisclosureSEC source: 0001636282-26-000078 · wk-form4_1780536719.xml · nonDerivative · entry 2 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 8,333 | $27.46 | $228,824.18 |
DisclosureSEC source: 0001636282-26-000078 · wk-form4_1780536719.xml · nonDerivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 78,333 | $0.00 Strike: $27.46 | $0.00 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · derivative · entry 9 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,667 Underlying: Common Stock · 78,333 shares Expires 2034-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F8 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 400 | $75.37 | $30,148.00 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 8 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,059 | $74.60 | $377,401.40 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 7 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.21 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 10,358 | $73.74 | $763,798.92 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 6 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,459 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.21 to $74.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 12,777 | $72.94 | $931,954.38 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 5 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,817 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.21 to $73.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 8,777 | $71.56 | $628,082.12 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 4 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,594 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.21 to $72.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 19,656 | $70.61 | $1,387,910.16 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 3 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,371 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.21 to $71.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 21,306 | $69.53 | $1,481,406.18 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 2 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,027 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.21 to $70.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 78,333 | $27.46 | $2,151,024.18 |
DisclosureSEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,958 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001636282-26-000030 · wk-form4_1775266209.xml · derivative · entry 3 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,542 Underlying: Common Stock · 7,958 shares Expires 2035-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. F2 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 7,958 | $50.00 | $397,900.00 |
DisclosureSEC source: 0001636282-26-000030 · wk-form4_1775266209.xml · nonDerivative · entry 2 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,958 | $21.66 | $172,370.28 |
DisclosureSEC source: 0001636282-26-000030 · wk-form4_1775266209.xml · nonDerivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:26 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $30.61 | $0.00 |
DisclosureSEC source: 0001636282-26-000002 · wk-form4_1768357592.xml · derivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:36 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 95,500 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001636282-25-000009 · wk-form4_1737149753.xml · derivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,500 Underlying: Common Stock · 95,500 shares Expires 2035-01-15 F1 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 22:34 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $27.46 | $0.00 |
DisclosureSEC source: 0001636282-24-000068 · wk-form4_1727822060.xml · derivative · entry 1 Sloan Sheldon · CIK 0002038798 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.